Skip to search formSkip to main contentSkip to account menu

LHRH, lysine(6)-doxorubicin

Known as: Lys(6)-LHRH-doxorubicin, Zoptarelin Doxorubicin, luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4- ((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)- 1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11- dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D- lysine)-, (2S-cis)- 
A peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

AN-152ZEN-008

Broader (2)

DoxorubicinGonadorelin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone‐releasing hormone analog (AN‐152)
2013
2013
Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108.
e15596 Background: AEZS-108 (AN-152, zoptarelin doxorubicin) is an LHRH-cytotoxic hybrid drug consisting of a Luteinizing Hormone… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)